# OnCo record paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017" ;
  schema:name "Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials"@en ;
  schema:description "Pooling 2,159 patients from six trials showed that which side of the colon a tumour started on decides whether an EGFR antibody helps at all: a clear survival gain on the left, none on the right."@en ;
  schema:url <https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1093/annonc/mdx175>, <https://pubmed.ncbi.nlm.nih.gov/28407110/>, <https://europepmc.org/article/MED/28407110> ;
  onco:tag "colorectal-evidence" ;
  schema:sameAs <https://doi.org/10.1093/annonc/mdx175> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Arnold D, Lueza B, Douillard JY, et al." ;
  onco:related <https://onco.cc/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/>, <https://onco.cc/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/>, <https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/>, <https://onco.cc/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/>, <https://onco.cc/biomarkers/ras-wild-type/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/nras/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/cms-subtypes/>, <https://onco.cc/terms/wild-type/> ;
  onco:trials <https://onco.cc/trials/paradigm/>, <https://onco.cc/trials/crystal-fire3/> ;
  onco:people <https://onco.cc/people/eric-van-cutsem/>, <https://onco.cc/people/josep-tabernero/>, <https://onco.cc/people/andres-cervantes/>, <https://onco.cc/people/heinz-josef-lenz/>, <https://onco.cc/people/volker-heinemann/>, <https://onco.cc/people/alan-venook/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .
